BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that second quarter 2022 financial results will be released after the market close on August 9, 2022.

Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia.

Aytu BioPharma, Inc. today announced that Chief Executive Officer Josh Disbrow and Chief Financial Officer Mark Oki will participate in the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022 at the InterContinental Hotel in Boston, MA.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022.

Modular Medical, Inc. today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2022 financial results and to provide a corporate update.

Within days of Health Canada issuing an Interim Order authorization for the Sal6830 SARS-CoV-2 Saliva Testing Kits, a Canadian family is grateful for a non-invasive testing option that offers the accuracy of PCR in less than 30 minutes.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its second quarter 2022 financial and operating results on Tuesday, August 9, 2022, following the close of trading.

Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the potential superior safety and efficacy of its Uttroside-B chemotherapeutic to treat liver cancer vs the current first line FDA approved drug.